Author

J. Geradts

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:spatial domain detection· 1 Research Focus:trajectory inference· 1

Frequent Co-Authors

A. D. D'Andrea· 1 shared A. G. Waks· 1 shared A. Hall· 1 shared A. Hobeika· 1 shared A. Nicholls· 1 shared B. Kochupurakkal· 1 shared C. A. Rebbeck· 1 shared C. C. Maley· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. D. D'Andrea

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development

M. D. Ryser, M. A. Greenwald, I. C. Sorribes, L. M. King, A. Hall, J. Geradts, D. L. Weaver, D. Mallo, S. Holloway, D. Monyak, G. Gumbert, S. Vaez-Ghaemi, E. Wu, K. A. Murgas, L. J. Grimm, , S. Hwang

This study reconstructs DCIS growth dynamics using somatic mutation topography, revealing a multiclonal, branching morphogenesis-like pattern consistent with a new Comet model of tumorigenesis.

bioRxiv · Oct 1, 2023 · PreprintCancer Biology

Creating a 'Timeline' of ductal carcinoma in situ to identify processes and biomarkers for progression towards invasive ductal carcinoma

C. A. Rebbeck, J. Xian, S. Bornelov, J. Geradts, A. Hobeika, H. Geiger, J. F. Alvarez, E. Rozhkova, A. Nicholls, N. Robine, H. K. Lyerly, G. J. Hannon

The paper generates a disease progression timeline for DCIS using gene expression data to identify early processes and biomarkers associated with progression to invasive breast cancer.

bioRxiv · Mar 1, 2022Cancer Biology

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

A. G. Waks, O. Cohen, B. Kochupurakkal, D. Kim, C. E. Dunn, J. Buendia Buendia, S. Wander, K. Helvie, M. R. Lloyd, L. Marini, M. E. Hughes, S. S. Freeman, S. P. Ivy, J. Geradts, S. Isakoff, , N. Wagle

This study identifies genomic reversion and increased DNA end resection as mechanisms of resistance to PARP inhibitors and platinum in BRCA1/2-mutant metastatic breast cancer, with RAD51 foci as a potential biomarker.

bioRxiv · Nov 10, 2019Cancer Biology